Open-label, long-term safety study of ARQ-154 foam 0.3% in subjects with seborrheic
dermatitis involving up to 20% total Body Surface Area (BSA). Study medication will be
applied by the qualifying subjects topically once daily for 52 weeks. Cohort 1 subjects are
rollover subjects from a prior ARQ-154 trial. Cohort 2 include treatment naive subjects.
Periodic clinic visits will include assessments for clinical safety, application site
reactions, and disease improvement or progression.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.